Clinical Trials Browser

Graft vs Host Disease, Leukemia, Lymphoma, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07195916 2026-04-14

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

Phase 1 Recruiting

280 enrolled

DermatologicGenitourinaryLymphoidOther hematologic neoplasm

Carcinoma, Renal Cell, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

Clinical Trials

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

CABAL2

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

ADAPT-HEM

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

TERZO

Sincerely20

T-START-M1

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study

Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma

T-START-NR

T-START-M1

A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study

A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma

Evaluate the Safety and Clinical Activity of HH2853

Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma

T-START-CR

A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

T-START-PR

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Amping up With PemJAK

Linperlisib Combined With Chidamide in Patients With PTCL

Anti-EBV TCR-T

A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)

CRESCENDO

A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

POLAR

Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

Study of Lacutamab in Peripheral T-cell Lymphoma

Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients

GVM±R in Patients With Relapsed or Refractory Aggressive NHL.

Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.

COURAGE

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)

A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL

Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma

Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma

Golidocitinib Plus CHOP in Newly Diagnosed PTCL

A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)